−/− mice infused with AngII. While adoptive transfer of B cells in Apoe −/− /Baffr −/− mice reversed atheroprotection in the absence of AngII, infusion of AngII in B cell replenished Apoe −/− /Baffr −/− mice unexpectedly prevented the progression of atherosclerosis. Atheroprotection observed in these mice was associated with a significant increase in regulatory CD1d hi CD5 + B cells, which produced high levels of interleukin (IL)-10 (B10 cells). Replenishment of Apoe −/− /Baffr −/− mice with Il10 −/− B cells reversed AngII-induced B cell-dependent atheroprotection, thus highlighting a protective role of IL-10 + regulatory B cells in this setting. Transfer of AngII type 1A receptor deficient (Agtr1a −/− ) B cells into Apoe Published: xx xx xxxx OPEN www.nature.com/scientificreports/ 2 Scientific RepoRts | 7: 4111 |
Despite decades of research and availability of various cholesterol lowering drugs, atherosclerosis remains the major cause of mortality in the world. Beyond the undisputable role of low-density lipoproteins (LDL) in disease initiation 1 , a substantial body of evidence point to an important role of immune mediated mechanisms in disease progression 2, 3 . Central to both atherosclerosis initiation and progression is the renin-angiotensin system, which plays a crucial role through several distinct mechanisms 4 . Angiotensin II (AngII), generated from Angiotensin I by Angiotensin Converting Enzyme (ACE), is the primary effector molecule of the renin-angiotensin system and is known to cause vascular cell dysfunction/activation, predisposing the vascular wall to inflammatory cell recruitment [5] [6] [7] . AngII controls various physiological and pathological functions 8 , and its role has been extended to the innate and adaptive immune systems where it modulates macrophage polarization 9 , T lymphocyte activation 10 , and the balance of helper T cell subsets 11 . Other studies unveiled a pivotal immune-modulatory role of the renin-angiotensin system in autoimmune diseases and in patients with heart failure 12, 13 . In those studies, blockade of AngII signaling suppressed auto-reactive Th1 and Th17 responses, promoted regulatory T cells 12 , or led to reduction of Th1/Th2 ratio and inflammatory cytokine production 13 .
AngII-induced atherosclerosis is mediated through type 1A receptor (Agtr1a) signaling in vascular cells 14 . Invalidation of AngII signalling in bone marrow-derived leukocytes plays a minor role 14 suggesting distinct roles of AngII on immune cell subsets. Indeed, while AngII induces T cell activation and proliferation, Agtr1a activation in macrophages has recently been shown to suppress their M1 pro-inflammatory phenotype, providing a protection in a mouse model of kidney injury 15 . The effects of AngII on B cell functions remain unknown. In the last decade, B cells were considered atheroprotective 16, 17 . More recently, we and others have reconsidered and redefined the role of B cells in atherosclerosis 18, 19 . The natural IgM secreting B1a subset was indeed shown to be atheroprotective 20, 21 . Conversely however, depletion of mature B2 cells using CD20 monoclonal antibody or genetic B2 cell deficiency in Baffr −/− mice resulted in reduced lesion development, indicating a proatherogenic role of the B2 cell subset 18, 19, 22 . The results are consistent with the pro-atherogenic role of T follicular helpher/ germinal center B cell activation 23 . Still, the B2 cell subset is a heterogeneous population of folicular B cells, innate-like marginal zone B cells and regulatory B cells (Bregs) with distinct developmental and (patho)physiological functions, and their selective roles in modulating the immune response during atherosclerosis are yet to be defined. Two studies recently addressed the role of regulatory B cells in hyperlipidemia-associated vascular disease. While we showed that endogenous IL-10 producing B cells do not alter the development of atherosclerosis in hypercholesterolemic Ldlr −/− mice 24 , another study reported IL-10-dependent protection against neointima formation after exogenous supplementation with lymph node-derived regulatory B cells 25 . The discrepancy between the two studies can be explained by important differences in the disease models and the source, state of activation and function of the B cells used in the experiments. Thus, additional studies are required to better understand the mechanisms that promote the development and maintenance of atheroprotective regulatory B cells. We became interested in a recent study by Saussine et al. that reported high levels of IL-10 producing B cells in active sarcoidosis, a finding that was associated with elevated levels of BAFF and ACE activity 26 . Given the importance of ACE activity in patients with coronary artery disease 27 , we attempted to understand the role of AngII (in combination with BAFF) in modulating B cell-mediated immune responses. We used Apoe −/− mice infused with AngII, a well-established model of AngII-induced vascular disease, to understand the role of AngII in modulating B cell function during the development of atherosclerosis. To address the selective effect of AngII on B2 cells, we adoptively transferred mature B cells into B2 cell-deficient Apoe −/− /Baffr −/− mice. The Apoe −/− / Baffr −/− model also has the advantage of displaying high levels of BAFF, and is particularly suited to address the impact of the interaction between AngII and BAFF on the function of mature B cells. Here, we report the surprising finding that AngII signals through Atgr1a on B cells to induce a B10 regulatory and anti-atherogenic phenotype, particularly in a high BAFF environment.
Materials and Methods
Animals. Experiments were conducted according to the European Community for experimental animal use guidelines (L358-86/609EEC) and were approved by the Ethical Committee of INSERM. All mice used in the experiments were male on a C57BL/6J background and maintained on a chow diet. Baffr −/− , Il10 −/− and Agtr1a −/− mice were obtained from Jackson Laboratories and were backcrossed more than 10 generations into a C57BL/6J background. CD45.1 and Apoe −/− mice were from Charles River. Apoe −/− mice were crossed with Baffr −/− mice to generate Apoe −/− /Baffr −/− mice. B cells were isolated from Wild-type (WT, C57BL/6J), Il10 −/− or Agtr1a −/− mice using negative isolation kit from Miltenyi, according to manufacturer's protocol. Recipient mice were injected with ~30 × 10 6 B cells 3-6 weeks before AngII infusion. AngII was infused subcutaneously in 12-14 weeks old mice via osmotic pumps at the concentration of 1 μg/kg/min for 7 or 28 days.
Atherosclerotic lesion. Atherosclerotic lesion assessment was performed on aortic sinus sections of mice
infused with AngII for 28 days or in similar age matched controls without AngII infusion. Animals that died before 28 days of AngII (or PBS) infusion were not analyzed. Plasma cholesterol was measured using a commercial cholesterol kit (Sigma). Quantification of lesion size was performed as described earlier 18 . In brief, the basal half of the ventricles and the ascending aorta were perfusion-fixed in situ with 4% paraformaldehyde. After then, they were removed, transferred to a PBS-30% sucrose solution, embedded in frozen OCT and stored at −70 °C. Serial 10-μm sections of the aortic sinus with valves (80 per mouse,) were cut on a cryostat, as previously described 28 . Of every 5 sections, one was kept for plaque size quantification after Oil red O staining. Thus, 16 sections spanning 800 μm stretch of the aortic root were used to determine mean lesion area for each mouse. Oil Red O positive lipid contents were quantified by a blinded operator using HistoLab software (Microvisions). Plasma cholesterol was measured using a commercial cholesterol kit (Biomerieux).
Systolic Blood Pressure Measurement. Systolic Blood Pressure (SBP) was measured in conscious mice using a tail cuff system (BP-2000 Visitech Systems), as previously described 29 . Measurements were always performed in the morning. In each animal, the system automatically performed 4 measurements first, which were not recorded, then, 10 consecutive measurements of SBP that were recorded. To avoid procedure-induced anxiety, and in each series of experiments, mice were accustomed to the tail cuff system during 3 consecutive days before basal SBP was recorded for 2 to 3 days (values were averaged) just prior mini-pump implantations. Then, SBP was measured at days 7, 14, 21 and 28, post-implantation.
Cell culture. B cells were isolated from splenocytes by negative selection using a cocktail of antibody coated magnetic beads (Miltenyi Biotec, Germany), and the purity was confirmed to be >95%. Purified B cells were stimulated in vitro with anti-CD40/IgM or LPS for 72 h. The supernatant was stored for ELISA, and for intracellular staining of IL-10, the cells were stimulated with a leukocyte activation cocktail containing golgi stop for the last 5 hours of culture before flow cytometric analysis. Violet 450 (Clone: 1B1). For intracellular cytokine staining, lymphocytes were stimulated in vitro with leukocyte activation cocktail (BD) according to the manufacturer's instructions for 4 h. Surface staining was performed before permeabilization using an intracellular staining kit (eBioscience). Intracellular IL-10 and IFN-γ was detected using IL-10-APC (Clone: JES5-16E3) and IFNγ-FITC (Clone: XMG1.2) antibodies, respectively.
ELISA. B cells were isolated from Apoe −/− and Apoe −/− /Baffr −/− mice transferred with B cells with or without AngII for 7 days or 28 days. Isolated B cells were stimulated in vitro with LPS or anti-CD40/IgM to determine IL-10 production. Cell free culture supernatants were frozen at −80 °C and then later examined for IL-10 production using a BD mouse IL-10 ELISA kit. sBAFF was determined by ELISA (R&D Systems) in the plasma samples from Apoe −/− and Apoe −/− /Baffr −/− mice with or without B cell transfer. Circulating antibody titers against MDA-LDL and CuOx-LDL were determined by chemiluminescent ELISA, as previously described 30-32 . qPCR. RNA was isolated from B cells from Apoe −/− /Baffr −/− mice transferred with B cells with or without AngII infusion. B cells isolated from WT or Agtr1a −/− mice were treated in vitro with AngII (10 μMol) for 72 hours with or without pre-treated with AT1a antagonist, Valsartan (10 μMol) or pErk inhibitor, PD98.059 (10 μMol) for two hours before stimulation with AngII. After 72 hours of in vitro stimulation, RNAs were extracted from B cells using Trizol reagent. In experiments where Apoe −/− /Baffr −/− mice were transferred with CD45.1 + B cells, the transferred B cells (CD45.1 + ) and the resident B cells (CD45.1 − ) were sorted using flow cytometry after 7 days of AngII infusion and the sorted cells were used for RNA isolation. cDNA was synthesised according to Qiagen reverse Transcription kit. Quantitative real-time PCR (Q-PCR) was performed on an ABI Prism 7700 (Applied Biosystems) in triplicates. CT for Gapdh (primers: Gapdh R, 5′-CGTCCCGTAGACAAAATGGTGAA-3′; Gapdh L, 5′-GCCGTGAGTGGAGTCATACTGGAACA-3′) was used to normalize gene expression. Primer sequences for Il10 and Agtr1a were as follows: Il-10 Forward: 5′-AAGTGATGCCCCAGGCA-3′, Il10 Reverse: 5′-TCTCACCCAGGGAATTCAAA-3′, Agtr1a Forward 5′-AAC AGC TTG GTG GTG ATC GTC-3′, Agtr1a Reverse: 5′-CAT AGC GGT ATA GAC AGC CCA-3′.
Statistics. All data are expressed as mean ± SE. Comparisons of 2 different groups were analyzed by
Mann-Whitney U test. ANOVA test with Bonferroni's post-test analysis was used for more than 2 groups. Statistical analyses were performed with Prism 5 software (GraphPad). P values < 0.05 was considered statistically significant.
Results

AngII promotes atheroprotective regulatory B cells. B2 cells promote experimental atherosclerosis.
Here, we aimed to investigate the role of B cells in athero-prone mice infused with AngII, which mimics some clinical situations in patients with coronary artery disease who may display increased ACE activity 27 . As previously reported in mice without AngII infusion 18 , treatment of Apoe −/− mice with anti-CD20 B cell-depleting monoclonal antibody also resulted in a significant reduction of atherosclerosis in mice infused with AngII for 28 days ( Supplementary Fig. S1a ), with no difference in plasma total cholesterol levels ( Supplementary Fig. S1b ). Consistent with acute B cell depletion, chronic B2 cell deficiency in Apoe −/− /Baffr −/− mice ( Supplementary Fig. S2 ) reduced the development of atherosclerosis compared to Apoe −/− mice, both in the absence and presence of AngII ( Fig. 1a,b ). Based on these results, we hypothesized that transfer of B cells into Apoe −/− /Baffr −/− mice would reverse atheroprotection. We therefore supplemented Apoe −/− /Baffr −/− mice with purified splenic CD19 + IgM + B cells ( Supplementary Fig. S3 ). Replenishment of Apoe −/− /Baffr −/− mice with wild-type B cells (WT, C57BL/6J) reversed the atheroprotective effects of B cell deficiency in the absence of AngII infusion, resulting in increased lesion formation ( Fig. 1a ). These results are consistent with the pro-atherogenic role of Baff receptor signaling in B cells 19 . However, to our surprise, adoptive transfer of B cells did not alter the development of atherosclerosis in Apoe −/− /Baffr −/− mice infused with AngII ( Fig. 1b ). Similar results were obtained when Apoe −/− /Baffr −/− mice were replenished with Apoe −/− B cells and infused with AngII (data not shown). Adoptive transfer of B cells in the presence or absence of AngII infusion did not have any effect on plasma total cholesterol levels ( Supplementary  Fig. S4 ). Moreover, transfer of B cells did not affect the blood pressure response to AngII ( Supplementary Fig. S5 ). In another series of experiments, we found that AngII infusion was able to increase the development of atherosclerosis in the aortic sinus of Apoe −/− Baffr −/− mice. However, replenishment of Apoe −/− Baffr −/− mice with wild type B cells completely abolished the atherogenic effect of AngII infusion ( Supplementary Fig. S6 ). Thus, our data indicate that the presence of AngII impairs the pro-atherogenic effect of B cells.
Recent studies reported a role for IgM secreting B1a B cells in atheroprotection 20 . Chronic B cell deficiency resulted in a significant reduction of anti-oxLDL IgG and IgM antibodies, and adoptive transfer of B cells restored the levels of both IgG and IgM anti ox-LDL antibodies, independently of AngII infusion ( Supplementary Fig. S7 ). Moreover, we did not find any difference in peritoneal B1a B cell numbers between the various groups of mice (data not shown).
Our flow cytometry analysis of splenocytes following B cell transfer demonstrated significant replenishment of the major B2 cell subsets (follicular and marginal zone B cells) in Apoe −/− /Baffr −/− mice (Figs 2a and S8). Notably however, B cell transfer was associated with a significant increase of CD1d hi CD5 + regulatory B cell subset only in mice infused with AngII (Figs 2b and S9 ). Further analysis of the immune response revealed a significant increase of CD4 + T cell activation and cytokine (IFN-γ/IL-17/IL-10) production after B cell transfer in the absence of AngII. In contrast, B cell transfer did not lead to any T cell activation in the presence of AngII (Figs 2c,d , S10 and S11). B cell supplementation into Apoe −/− /Baffr −/− mice did not significantly affect CD4 + CD25 high Foxp3 + regulatory T cell population, regardless of AngII infusion (data not shown). Collectively, these results point to an unexpected function of AngII in promoting atheroprotective regulatory B cells. Since the effect is observed in a context of high BAFF levels (Apoe −/− /Baffr −/− ), we suspected a synergistic effect between AngII and BAFF.
AngII and BAFF synergistically induce IL-10 production in B cells. Next, we investigated if the increase of CD1d hi CD5 + B cells in Apoe −/− /Baffr −/− mice following AngII infusion was due to an expansion of endogenous immature residual B cells or to the population of adoptively transferred B cells being polarized toward a regulatory phenotype. To answer this question, we transferred CD45.1 splenic B cells into Apoe −/− / Baffr −/− mice with or without AngII infusion for 7 days. We found a significant increase of CD1d hi CD5 + B cells in the AngII infused group (Fig. 3a) . Consistent with a regulatory CD1d hi CD5 + phenotype, AngII also induced IL-10 production in B220 + /CD19 + B cells (Figs 3b and S12, and data not shown), and CD1d hi CD5 + B cells ( Supplementary Fig. S13 ), but not in B1 cells ( Supplementary Fig. S14 ). Amongst the transferred CD45.1 + B cells in Apoe −/− /Baffr −/− mice, IL-10 levels were significantly higher in the mice infused with AngII ( Fig. 3c) , suggesting that the transferred mature B cells produced IL-10 upon AngII stimulation. Our results were verified by qPCR (Figs 3d and S15) and by ELISA (Fig. 3e ).
Interestingly, we also observed a significant increase of IL-10 production in Apoe −/− /Baffr −/− mice transferred with B cells in the absence of AngII, although to a lower extent compared with AngII-treated mice (Figs 3b, S12 and S16). In fact, Baffr deficiency results in a significant increase of serum BAFF levels ( Supplementary Fig. S17 ) and recent studies demonstrated that both murine and human B cells can be induced to produce IL-10 upon stimulation with BAFF 33, 34 . We therefore addressed the potential synergy between AngII and BAFF in promoting a B10 phenotype. We transferred B cells to either Apoe −/− mice ('normal' plasma BAFF levels) or Apoe −/− /Baffr −/− mice (elevated BAFF levels), and treated the mice with PBS or AngII for 7 days. Our flow cytometry analysis of splenocytes from these mice showed a significant increase of IL-10 production by B cells, especially in B cell replenished Apoe −/− /Baffr −/− mice with AngII infusion ( Supplementary Fig. S12b ). Our ELISA results showed that there was a significant increase of IL-10 production in AngII infused Apoe −/− mice; however, IL-10 production was more pronounced in Apoe −/− /Baffr −/− mice infused with AngII ( Supplementary Fig. S16 ), revealing a synergy between AngII and BAFF in the induction of B10 cells.
Regulatory B cells generated in response to
AngII are atheroprotective through their production of IL-10. We hypothesized that AngII-induced regulatory B cells prevented the progression of atherosclerosis through their IL-10 production. To test this hypothesis, we re-supplemented Apoe −/− /Baffr −/− mice with either Il-10 +/+ or Il-10 −/− B cells, followed by AngII infusion for 28 days. Adoptive transfer of Apoe −/− / Baffr −/− mice with Il-10 −/− B cells did not alter BAFF levels ( Supplementary Fig. S17b ) but resulted in a significant reduction of IL-10 production in splenocytes (Fig. 4a ), splenic B cells (Figs 4b and S18) and CD1d hi CD5 + B cells (data not shown), and was associated with a significant acceleration of atherosclerosis (Fig. 4c ). These results demonstrate that AngII induced B10 cells are endowed with atheroprotective properties.
Agtr1a deficiency in B cells abrogates the atheroprotective B10 phenotype. Agtr1a is known to
mediate several biological effects of AngII 35, 36 . In accordance with a previous publication 10 , we observed Agtr1a gene expression in splenic purified B cells (Fig. 5a ). We therefore investigated if the AngII-induced atheroprotective effects of B cells were mediated by Agtr1a. Adoptive transfer of Agtr1a −/− B cells into AngII infused Apoe −/− / Baffr −/− mice abrogated the atheroprotection observed in Apoe −/− /Baffr −/− mice transferred with WT B cells, despite no changes in plasma total cholesterol levels (Fig. 5b,c) . We also observed a significant 38% reduction of IL-10 production by B cells (Figs 5d, S19 and S20) in mice transferred with Agtr1a −/− B cells. In vitro stimulation of WT B cells with AngII induced Il-10 mRNA, which was abrogated by Agtr1a deficiency and by valsartan, an antagonist of Agtr1a (Fig. 5e ). We further attempted to understand the pathway through which Agtr1a induces IL-10 production. ERK activation is critical for the induction of IL-10 in many cell types 37 and AngII is known to induce the ERK pathway 38, 39 . Accordingly, ERK inhibition using PD98.059 abolished AngII induced Il-10 mRNA expression in B cells (Fig. 5e ). Our results identify a previously unsuspected role for AngII in inducing IL-10 production by B cells through Agtr1a-dependent activation of ERK.
Discussion
The present study reveals a synergistic effect between AngII and BAFF in inducing atheroprotective B10 cells via AT1A receptor. Our conclusion is supported by four major findings. Consistent with previous reports on the pro-atherogenic role of BAFF receptor signaling in B cells 18, 19, 21 , we observed that replenishment of Apoe −/− /Baffr −/− mice with mature B cells significantly promoted atherosclerosis. However, to our surprise replenishment of Apoe −/− /Baffr −/− mice with mature B cells in did not reverse atheroprotection when mice were infused with AngII. Consistent with this finding, AngII infusion increased atherosclerosis in the aortic sinus of Apoe −/− /Baffr −/− mice but AngII pro-atherogenic effect was lost in mice replenished with mature B cells. Recent published studies have shown differential roles of B cell subsets in the development of atherosclerosis. While mature B2 cells are shown to be proatherogenic, the IgM secreting B1a subset is shown to be atheroprotective 20, 22 . The latter subset was unlikely to be involved in the AngII-dependent atheroprotective B cell phenotype because restoration of (anti-oxLDL) IgM antibody levels following B cell transfer in Apoe −/− / Baffr −/− mice was comparable in mice with or without AngII. Though adoptive transfer of mature B cells in Apoe −/− /Baffr −/− mice led to similar restoration of B cell subsets in presence or absence of AngII, we observed a profound increase of CD1d hi CD5 + regulatory B cell subset only in mice infused with AngII. This was associated with a reduction in CD69 and CD44high expression by CD4+ T cells, suggesting that the expanded regulatory B cell population (under AngII) inhibited CD4+ T cell activation. Our data underlines the tight cooperation between adaptive T and B cell subsets 40 in regulating atherogenic immune responses.
We identified IL-10 production by B cells as responsible for the atheroprotective phenotype of AngII-induced regulatory B cells, and revealed a requirement for both AngII and BAFF in promoting atheroprotective B10 cells. Therefore, our data indicate that B10 cells control atherosclerosis under defined conditions. There are several clinical settings where those conditions are met and may promote the generation of disease modulating B10 cells. It is noteworthy that in patients with active chronic sarcoidosis, elevated levels of BAFF and ACE were strongly associated with increased IL-10 producing B cells 26, 41 . CD20 mAb therapy in humans is known to increase BAFF levels and the naïve (CD19 + IgD + ), transitional or plasmablast (CD19 + IgD + CD24 hi CD38 hi ) B cells that recover after B cell depletion are responsive to BAFF and are associated with a better therapeutic effect 42, 43 . Interestingly, regulatory B cells in humans are identified as CD19 + CD24 hi CD38 hi44 . In mice, additional membrane markers of regulatory B cells, non-investigated in our study, have been identified including TIM-1 45 and CD9 46 . It is plausible that the B cells that regenerate after B cell depletion therapy acquire a regulatory phenotype due to high BAFF levels. Our results suggest that patients who undergo B cell depletion therapy would be protected from atherosclerosis and the B cells that regenerate in the presence of high BAFF and AngII (patients with atherosclerosis have high ACE activity) will enhance the protective effects due to their improved regulatory functions. Recently, Jackson et al. have reported another potential mechanism of atheroprotection induced by BAFF. Using several genetically modified mouse models on Apoe −/− background, they showed that BAFF overexpression increased anti-oxLDL IgM antibody plasma levels through TACI activation 47 . However, the functional effect of those B cell subsets in humans is yet to be explored. Increased BAFF level is associated with various autoimmune diseases and neutralizing BAFF is considered to be a potential therapeutic target for many of these diseases 48 . Our results show that therapeutic strategies aimed at neutralizing BAFF should be considered with caution since BAFF also downregulates immune responses through induction of IL-10. All our results were obtained in a BAFF receptor deficient environment and it is important to confirm them in other settings. In addition, as our study was performed in mice at an early stage of atherosclerosis, further studies are required to confirm our findings in more advanced atherosclerosis.
Recently, Chan et al. reported a reduction of AngII-induced hypertension in Apoe −/− /Baffr −/− mice compared with control Apoe −/− /Baffr +/+ mice. In addition, B cell supplementation in Apoe −/− /Baffr −/− mice worsened hypertension 49 . In our study, we found a slight but non-significant trend toward a lower increase of blood pressure in Apoe −/− /Baffr −/− mice compared to Apoe −/− mice after infusion with AngII. B cell transfer into Apoe −/− / Baffr −/− mice did not affect the blood pressure response to AngII infusion. This apparent discrepancy between our results and those of Chan et al. with regard to the hypertensive phenotype could be explained by the different doses of AngII used in the 2 studies (1 μg/kg/min or 1.4 mg/kg/day versus 0.7 mg/kg/day).
AngII infusion accelerates atherosclerosis and blockade of the renin-angiotensin system is protective. However, the proatherogenic effects of AngII have been shown to depend on age, sex, AngII dose, cholesterolemia, duration of treatment and the arterial site at which lesion size was assessed 50-52 . Weiss et al. have shown that after 4 weeks of Ang II infusion, the increase of atherosclerotic plaque size was modest in the ascending thoracic aorta and was much more pronounced in the descending thoracic and abdominal aorta 53 . Similarly, Zhou et al. found that the proatherogenic effect of AngII was much more important in the descending aorta than in the aortic sinus 54 . Lesion size was not statistically different between mice infused with PBS as compared to mice infused with AngII in Fig. 1a,b . However, experiments with and without AngII were not performed at the same time and should not be compared. When experiments with and without AngII were conducted simultaneously in immunodeficient apoe −/− Baffr −/− mice, we confirmed that AngII accelerated atherosclerosis in the aortic sinus. Interestingly, supplemention of apoe −/− Baffr −/− mice with B cells abrogated the pro-atherogenic effect of AngII due to expansion of an IL-10-producing B cell population. Together, the data suggest differential effects of AngII depending on the target cells, being pro-atherogenic in vascular cells and anti-atherogenic in immune cells, like B cells. Previous experiments using bone marrow transplantation in Ldlr −/− mice are in agreement with our findings. Cassis et al. found that AngII type 1A receptor engagement on vascular cells clearly promoted atherosclerosis, but the role of AngII type 1A receptor expressed by hematopoietic cells remained unclear 14 . This could be accounted for by the differential effects of AngII type 1A receptor engagement on different leukocyte subsets. For example, AngII may activate Th1 T cells 10 but AngII type 1A receptor also limits M1 macrophage polarization in part through a reduction of IL1 receptor activation 15 . Thus, the function of AT1A may not be solely proinflammatory. In our study, we found that AngII type 1A receptor activation induced a B10 regulatory profile. One of the pathways via which AngII mediates its cellular effects involves the activation of ERK downstream of AT1A 38, 39 . Furthermore, ERK activation is the common pathway utilized by most immune cells to induce IL-10 production 37 . Our findings extend those results and provide evidence for an ERK-dependent induction of IL-10 production by B cells in response to activation of AT1A receptor.
In summary, our results reveal a previously unsuspected synergistic role between AngII and BAFF in inducing atheroprotective B10 cells. Exploiting those pathways may lead to novel therapeutic strategies to limit atherosclerosis in humans.
